Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Depreciation and Depletion (2019 - 2023)

Benitec Biopharma's Depreciation and Depletion history spans 5 years, with the latest figure at $19000.0 for Q3 2023.

  • For Q3 2023, Depreciation and Depletion fell 54.76% year-over-year to $19000.0; the TTM value through Sep 2023 reached $121000.0, down 22.93%, while the annual FY2022 figure was $167000.0, 27.71% down from the prior year.
  • Depreciation and Depletion for Q3 2023 was $19000.0 at Benitec Biopharma, down from $42000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $67000.0 in Q4 2020 and bottomed at -$105000.0 in Q2 2020.
  • The 5-year median for Depreciation and Depletion is $51000.0 (2019), against an average of $36000.0.
  • The largest annual shift saw Depreciation and Depletion surged 149.52% in 2021 before it plummeted 88.46% in 2022.
  • A 5-year view of Depreciation and Depletion shows it stood at $51000.0 in 2019, then surged by 31.37% to $67000.0 in 2020, then fell by 17.91% to $55000.0 in 2021, then dropped by 23.64% to $42000.0 in 2022, then tumbled by 54.76% to $19000.0 in 2023.
  • Per Business Quant, the three most recent readings for BNTC's Depreciation and Depletion are $19000.0 (Q3 2023), $42000.0 (Q3 2022), and $6000.0 (Q2 2022).